取消COPD维持吸入药物事前授权对指南一致性用药的影响
该研究基于加拿大不列颠哥伦比亚省行政健康数据,纳入47,583例COPD患者,采用中断时间序列分析评估2020年7月取消LAMA事前授权并限制ICS/LABA覆盖的政策效果。政策实施30个月后,ICS/LABA使用比例下降1.3%,LAMA使用比例上升0.8%,LAMA起始作为维持治疗的比例增加34.8%,总药物成本未变。
要点
- 取消LAMA事前授权与限制ICS/LABA覆盖后,指南一致性用药改善。
- LAMA起始作为维持治疗的比例显著增加34.8%。
- 总联合药物成本在政策前后无变化。
核心结论
- 不列颠哥伦比亚省的药物覆盖政策变化与指南一致性维持吸入药物使用改善相关。
研究设计与样本
- 基于人群的队列研究,使用省级行政健康数据,纳入47,583例COPD患者,平均年龄71.5岁,女性占46.5%,平均随访31.7个月,采用中断时间序列分析。
主要发现
- 政策后30个月,ICS/LABA使用比例下降1.3%(95%CI -2.4, -0.3),LAMA使用比例上升0.8%(95%CI 0.1, 1.6)。
- ICS/LABA的发放罐数、PDC或停药比例无显著变化。
- LAMA平均每千名患者发放罐数增加9.8(95%CI 1.0, 18.7),PDC增加1.5%(95%CI 0.5, 2.4)。
- LAMA(再)起始比例增加0.2%(95%CI 0.02, 0.3),LAMA起始作为维持治疗的比例增加34.8%(95%CI 22.3, 48.6)。
- 总联合药物成本无变化。
临床怎么用
- 政策调整可促进COPD患者使用指南推荐的LAMA作为一线维持治疗,并减少不推荐的ICS/LABA使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most patients with chronic obstructive pulmonary disease (COPD) do not receive maintenance inhaled therapies in concordance with evidence-based clinical guidelines. Long-acting muscarinic antagonists (LAMA), the recommended first-line therapy, is underused, while inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) are often used in discordance with clinical guidelines. In July 2020, British Columbia's (BC) universal drug plan removed prior authorization requirements for coverage for LAMA medications and restricted coverage for ICS/LABA. RESEARCH QUESTION: What is the impact of this policy change on guideline-concordant maintenance inhaled medication use? STUDY DESIGN AND METHODS: In a population-based cohort study using provincial administrative health data, we identified patients with COPD using a validated case definition and followed them from January 2019 (18 months pre-policy) to December 2022 (30 months post-policy). Using interrupted time series analysis, we evaluated the monthly proportion of patients filling a prescription for ICS/LABA and LAMA, mean canisters dispensed, proportion of days covered (PDC), rates of ICS/LABA discontinuation, LAMA (re)initiation, and initiating LAMA as first maintenance therapy. We report absolute differences between observed and counterfactual outcomes at study end. RESULTS: The cohort included 47,583 patients with COPD (mean 71.5 years, 46.5% female, 31.7 months mean follow-up). Thirty months post-policy change, ICS/LABA use decreased by -1.3% (95% CI -2.4, -0.3) and LAMA use increased by 0.8% (95% CI 0.1, 1.6). There was no significant change in the number of ICS/LABA canisters dispensed, PDC or proportion discontinuing ICS/LABA. Mean LAMA canisters dispensed increased by 9.8 per 1,000 patients (95% CI 1.0, 18.7) and PDC increased by 1.5% (95% CI 0.5, 2.4). (Re)initiation of LAMA or initiating LAMA as maintenance therapy increased by 0.2% (95% CI 0.02, 0.3) and 34.8% (95% CI 22.3, 48.6), respectively. Total combined drug costs did not change. INTERPRETATION: Changes to drug coverage in BC were associated with improved guideline-concordant medication use.
引用
- Johnson KM, Cheng L, Duan KI, et al. The impact of removing prior authorization for guideline-concordant maintenance inhaled medications for COPD: a population-based cohort study. Chest. 2026. PMID: 42988324. doi:10.1016/j.chest.2026.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。